Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 163

Sort by

Sort Order Select

Journal Articles

Racial and ethnic disparities in u.S. chronic lymphocytic leukemia clinical trial enrollment: A participation-to-prevalence analysis

Anushka Bhaskar, Anna Oh, William Shomali, Gabriel Mannis, Michaela Liedtke, Jason Gotlib, Tait Shanafelt, Bita Fakhri

Blood (2025) 146 (Supplement 1): 6308.

https://doi.org/10.1182/blood-2025-6308

Published: 2025

Journal Articles

Effect of avapritinib on skin lesions in patients with advanced systemic mastocytosis using a novel, artificial intelligence-based technology

Blood (2025) 146 (Supplement 1): 2030.

https://doi.org/10.1182/blood-2025-2030

Published: 2025

Journal Articles

Avapritinib achieves deep and durable symptom control with a well-tolerated safety profile in ism: Long-term outcomes from pioneer

Blood (2025) 146 (Supplement 1): 2024.

https://doi.org/10.1182/blood-2025-2024

Published: 2025

Journal Articles

A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia

Jason Gotlib, John Mascarenhas, Raajit Rampal, Abdulraheem Yacoub, Hongfei Li, Josu Santamaria, Molly Halloran, Naveen Pemmaraju

Blood (2025) 146 (Supplement 1): 2051.

https://doi.org/10.1182/blood-2025-2051

Published: 2025

Journal Articles

Novel therapeutics for SF3B1 mutant cancers which exploit the missplicing of DCAF16

Blood (2025) 146 (Supplement 1): 1474.

https://doi.org/10.1182/blood-2025-1474

Published: 2025

Journal Articles

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Blood (2025) 146 (Supplement 1): 484.

https://doi.org/10.1182/blood-2025-484

Published: 2025

Journal Articles

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Blood (2025) 146 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2025-1024

Published: 2025

Journal Articles

Avapritinib treatment of patients with advanced systemic mastocytosis: 4-year safety, effect on bone and first-line efficacy results of the pathfinder clinical study

Andreas Reiter, Tracy George, Deepti Radia, Michael Deininger, Johannes Luebke, Hui-Min Lin, Ilda Bidollari, Joana Caetano-Lopes, Guang Yang, Amber King, Saša Dimitrijević, Daniel Deangelo, Jason Gotlib

Blood (2025) 146 (Supplement 1): 1022.

https://doi.org/10.1182/blood-2025-1022

Published: 2025

Journal Articles

Molecular characterization of patients (pts) with myeloproliferative neoplasms treated with INCA033989 demonstrates selective targeting of CALR mutant hematopoietic cells

Bethan Psaila, Jyoti Nangalia, Jason Gotlib, Claire Harrison, John Mascarenhas, Erin Crowgey, Betty Lamothe, Chenwei Tian, Evan Braunstein, Steffen Koschmieder

Blood (2025) 146 (Supplement 1): 71.

https://doi.org/10.1182/blood-2025-71

Published: 2025

Journal Articles

Long-term rusfertide treatment in polycythemia vera: Initial results from the phase 2 THRIVE extension study

Naveen Pemmaraju, Andrew Kuykendall, Ellen Ritchie, Jason Gotlib, Jeanne Palmer, Aaron Gerds, David Oubre, Prof. Uttam Kumar Nath, Gregory Vosganian, Suneel Gupta, Pedro Oyuela, Sarita Khanna, Arturo Molina, Marina Kremyanskaya

Blood (2025) 146 (Supplement 1): 3810.

https://doi.org/10.1182/blood-2025-3810

Published: 2025

Journal Articles

The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results

Blood (2025) 146 (Supplement 1): 3795.

https://doi.org/10.1182/blood-2025-3795

Published: 2025

Journal Articles

Improved overall survival in patients with advanced systemic mastocytosis treated with avapritinib versus real-world therapy based on mutation-adjusted risk score (MARS) stratification

Blood (2025) 146 (Supplement 1): 5595.

https://doi.org/10.1182/blood-2025-5595

Published: 2025

Journal Articles

Changes in long-term bone health in patients receiving avapritinib for the treatment of indolent systemic mastocytosis in the pioneer study

Mariana Castells, Vishnu Sundaresh, Jason Gotlib, Tsewang Tashi, Vito Sabato, Cristina Bulai Livideanu, Cem Akin, Deepti Radia, Frank Siebenhaar, Daniel Deangelo, Tracy George, Hui-Min Lin, Janet Hong, Ashley Doyle, Guang Yang, Rachel Erlich, Kate Newberry, Benjamin Lampson, Ivan Alvarez-Twose

Blood (2025) 146 (Supplement 1): 5582.

https://doi.org/10.1182/blood-2025-5582

Published: 2025

Journal Articles

Diagnostic evolution in systemic mastocytosis: Clinical impact of who 2022 criteria on smoldering systemic mastocytosis identification in pioneer

Tracy George, Mariana Castells, Cem Akin, Hanneke Oude Elberink, Karin Hartmann, Sigurd Broesby-Olsen, Frank Siebenhaar, Hui-Min Lin, Janet Hong, Benjamin Lampson, Jason Gotlib

Blood (2025) 146 (Supplement 1): 5578.

https://doi.org/10.1182/blood-2025-5578

Published: 2025

Journal Articles

An analysis of clonal dynamics in patients with indolent systemic mastocytosis treated with avapritinib in the pioneer study

Jens Panse, Tsewang Tashi, Jason Gotlib, Mariana Castells, Ivan Alvarez-Twose, Cem Akin, Cristina Bulai Livideanu, Vito Sabato, Juliana Schwaab, Andreas Reiter, Sigurd Broesby-Olsen, Frank Siebenhaar, Hui-Min Lin, Janet Hong, Benjamin Lampson, Guang Yang, Tracy George, Deepti Radia

Blood (2025) 146 (Supplement 1): 5573.

https://doi.org/10.1182/blood-2025-5573

Published: 2025

Journal Articles

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Nicola Polverelli, Juan Carlos Hernández-Boluda, Francesco Onida, Carmelo Gurnari, Kavita Raj, Tomasz Czerw, Michelle Kenyon, Marie Robin, Katja Sockel, Annalisa Ruggeri, Isabel Sánchez-Ortega, Daniel A. Arber, Luca Arcaini, Fernando Barroso Duarte, Giorgia Battipaglia, Yves Chalandon, Fabio Ciceri, Nicholas C. P. Cross, Joanna Drozd-Sokolowska, Vaneuza Funke, Nico Gagelmann, Naseema Gangat, Jason Gotlib, Paola Guglielmelli, Claire Harrison, Gabriela Hobbs, Tania Jain, Joseph D. Khoury, Jean Jacques Kiladjian, Nicolaus Kröger, Luca Malcovati, Massimo Martino, Ruben Mesa, Attilio Orazi, Eric Padron, Francesca Palandri, Francesco Passamonti, Mrinal M. Patnaik, Naveen Pemmaraju, Deepti H. Radia, Andreas Reiter, Domenico Russo, Christof Scheid, Ayalew Tefferi, Alessandro M. Vannucchi, Daniel H. Wiseman, Ibrahim Yakoub-Agha, Donal P. McLornan

Blood (2025) 145 (22): 2561–2573.

https://doi.org/10.1182/blood.2024028000

Published: 2025

Includes: Supplemental data

Journal Articles

Introduction to a How I Treat series on myeloproliferative neoplasms

Jason Gotlib

Blood (2025) 145 (16): 1707–1709.

https://doi.org/10.1182/blood.2025028401

Published: 2025

Journal Articles

Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

Blood (2024) 144 (Supplement 1): 4569.1.

https://doi.org/10.1182/blood-2024-194550

Published: 2024

Journal Articles

A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Andrew T. Kuykendall, Somedeb Ball, Jason Gotlib, Cecilia Y. Arana Yi, Tsewang Tashi, Raajit Rampal, Daniel J DeAngelo, Virginia O. Volpe, Kristen M. Pettit, Gerard Hoehn, Sasa Dimitrijevic, Rami S. Komrokji, Eric Padron

Blood (2024) 144 (Supplement 1): 4569.2.

https://doi.org/10.1182/blood-2024-211148

Published: 2024

Journal Articles

Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)

Blood (2024) 144 (Supplement 1): 659.

https://doi.org/10.1182/blood-2024-193678

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Racial and ethnic disparities in u.S. chronic lymphocytic leukemia clinical trial enrollment: A participation-to-prevalence analysis

Effect of avapritinib on skin lesions in patients with advanced systemic mastocytosis using a novel, artificial intelligence-based technology

Avapritinib achieves deep and durable symptom control with a well-tolerated safety profile in ism: Long-term outcomes from pioneer

A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia

Novel therapeutics for SF3B1 mutant cancers which exploit the missplicing of DCAF16

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Avapritinib treatment of patients with advanced systemic mastocytosis: 4-year safety, effect on bone and first-line efficacy results of the pathfinder clinical study

Molecular characterization of patients (pts) with myeloproliferative neoplasms treated with INCA033989 demonstrates selective targeting of CALR mutant hematopoietic cells

Long-term rusfertide treatment in polycythemia vera: Initial results from the phase 2 THRIVE extension study

The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results

Improved overall survival in patients with advanced systemic mastocytosis treated with avapritinib versus real-world therapy based on mutation-adjusted risk score (MARS) stratification

Changes in long-term bone health in patients receiving avapritinib for the treatment of indolent systemic mastocytosis in the pioneer study

Diagnostic evolution in systemic mastocytosis: Clinical impact of who 2022 criteria on smoldering systemic mastocytosis identification in pioneer

An analysis of clonal dynamics in patients with indolent systemic mastocytosis treated with avapritinib in the pioneer study

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Introduction to a How I Treat series on myeloproliferative neoplasms

Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only